Study of PYX-106 in Solid Tumors
← catalyst calendarSponsored by Pyxis Oncology, Inc (industry) · PYXS — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
47actual
Sites
20
Countries
Belgium, Spain, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-05-23 | actual | When the study began enrolling |
| Primary completion | May 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2023-02-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Solid Tumor
Intervention
- Drug: PYX-106
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants Who Experience a Dose-Limiting Toxicity (DLT)
measured Day 1 to Day 28
Number of Participants Who Experience an Adverse Event (AE)
measured Day 1 up to approximately 19 months
Permalink · PYXS's whole pipeline · Catalyst calendar · Every registered study · What changed